U.S. Professional Services Stock News

Over the last 7 days, the United States market has dropped 3.5%, but it has seen a rise of 14% over the past year, with earnings projected to grow by 15% annually in coming years. In light of these conditions, identifying stocks with strong financial health and growth potential is crucial for investors seeking opportunities beyond mainstream options. Penny stocks, though an outdated term, still represent a niche investment area that can offer surprising value and potential returns when backed...

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this dynamic environment, identifying stocks that are not only resilient but also poised for growth can be a rewarding strategy for investors seeking potential opportunities.

Over the last 7 days, the United States market has experienced a 3.5% drop, although it has shown resilience with a 14% rise over the past year and an earnings growth forecast of 15% annually. In this context, dividend stocks that offer consistent payouts and potential for long-term appreciation can be attractive options for investors seeking stability amidst fluctuating market conditions.

Steel Dynamics (NasdaqGS:STLD) announced that long serving directors Richard P. Teets, Jr. and Gabriel L. Shaheen plan to retire from its board at the upcoming annual meeting. The changes will reduce long term board presence and open seats for new directors once shareholders vote at the meeting. Both directors have served during key phases of the company’s development in the steel and metals recycling sector. For you as an investor, this matters because board composition shapes how Steel...

New independent cost impact model evaluates Indivior's extended-release buprenorphine (SUBLOCADE) in U.S. correctional facilities. The model suggests SUBLOCADE, a monthly injectable for opioid use disorder, may meaningfully cut staff time and related costs versus other treatments. Findings, published in a peer reviewed journal, highlight potential operational benefits and treatment access gains for jails and prisons. For investors watching Indivior Pharmaceuticals (NasdaqGS:INDV), this...

Wondering whether CubeSmart's current share price still offers value, or if most of the opportunity has already been priced in? This article breaks down what the numbers actually say about the stock. CUBE has had a mixed run recently, with a 3.4% decline over 7 days, a 12.7% decline over 30 days, a 1.4% gain year to date, and an 11.4% decline over the last year, which can change how the market views its risk and return profile. Recent coverage has focused on CubeSmart's share price moves and...

Wondering if DRDGOLD at around US$27.65 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price might imply. The stock has returned 1.7% over the last 7 days, while the 30 day return sits at a 28.9% decline, against an 8.8% decline year to date and an 81.5% return over the past year, with a very large 3 year and 226.1% 5 year return. Recent coverage has focused on DRDGOLD as part of broader gold and precious metals...

Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings. The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio. Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...

CIM Real Estate Finance Trust (OTCPK:CMRF) has wrapped up FY 2025 with fourth quarter revenue of US$97.9 million and basic EPS of US$0.07, giving investors a clean snapshot of how the year finished. Over recent periods, revenue has shifted from US$121.4 million in Q3 2024 to US$106.2 million in Q4 2024, then to US$106.4 million in Q1 2025, US$107.2 million in Q2 2025, US$104.5 million in Q3 2025 and US$97.9 million in Q4 2025, while quarterly EPS moved from US$0.02 to an interim loss before...

If you are wondering whether Roku's current share price reflects its true worth, you are not alone; the stock's recent moves have raised fresh questions about what you are really paying for. Roku closed at US$88.23, with returns of a 9.8% decline over 7 days, a 10.3% decline over 30 days and an 18.8% decline year to date, set against a 25.3% gain over 1 year and 34.3% over 3 years, while the 5 year return stands at a 73.1% decline. Recent headlines around Roku have focused on its position in...

If you are wondering whether Alphatec Holdings at around US$11 is a bargain or a value trap, the key is to look past the headline share price and into how it stacks up on valuation. The stock has seen a 9.5% decline over the last week, a 19.2% decline over the last 30 days, and is down 47.0% year to date, even though the 1 year return sits at 8.5%. These moves sit against a backdrop of ongoing interest in medical equipment companies, with investors weighing up growth potential in specialist...

If you are wondering whether XPeng's share price reflects its real worth, or if the market is mispricing the story, this article walks you through what the numbers are actually saying. XPeng's stock last closed at US$16.72, with returns of an 11.4% decline over 7 days, 4.8% decline over 30 days, 18.2% decline year to date and 19.3% decline over 1 year, set against a 52.0% gain over 3 years and 53.6% decline over 5 years. These mixed returns sit against a backdrop of ongoing headlines about...

We wouldn't blame Hewlett Packard Enterprise Company ( NYSE:HPE ) shareholders if they were a little worried about the...

Investors were underwhelmed by the solid earnings posted by Kanzhun Limited ( NASDAQ:BZ ) recently. We did some digging...

MoonLake Immunotherapeutics: recent stock performance snapshot MoonLake Immunotherapeutics (MLTX) has seen mixed trading moves recently, with the stock down 2.3% over the past day and roughly 3.3% over the past month, while showing a gain of about 28% in the past 3 months. See our latest analysis for MoonLake Immunotherapeutics. The current share price of $16.93 sits alongside a 90 day share price return of 28.45% and a year to date share price return of 41.67%. In contrast, the 1 year total...

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this fluctuating environment, identifying stocks that are potentially undervalued and have notable insider activity can be key to uncovering promising opportunities in the small-cap sector.

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks requires a focus on companies with strong innovation potential and robust financial health that can capitalize on long-term trends despite short-term fluctuations.

The United States market has experienced a 3.5% decline over the past week, yet it remains up by 14% over the last year, with earnings projected to grow by 15% annually. In this context, finding stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on long-term growth prospects amidst fluctuating market conditions.

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has risen by 14% over the past year with earnings projected to grow by 15% annually in the coming years. In this environment, growth companies with high insider ownership can be particularly appealing as they may align management's interests with shareholders and potentially drive significant earnings growth.

Over the last 7 days, the U.S. market has dropped 3.5%, but it has risen by 14% over the past year, with earnings forecasted to grow annually by 15%. Investing in penny stocks — a term that may feel outdated yet remains relevant — can still provide access to growth opportunities, especially within smaller or newer companies. By focusing on those with robust financials and clear growth potential, investors can uncover valuable opportunities among these lesser-known stocks.

Over the last 7 days, the United States market has dropped 3.5%, yet it has seen a robust rise of 14% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering undiscovered gems worth exploring in March 2026.

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this fluctuating environment, dividend stocks that offer substantial yields can provide a reliable income stream and potential stability for investors seeking consistent returns amidst market volatility.

The recent 10% drop in Candel Therapeutics, Inc.'s ( NASDAQ:CADL ) stock could come as a blow to insiders who purchased...

Insiders who purchased Vera Bradley, Inc. ( NASDAQ:VRA ) shares in the past 12 months are unlikely to be deeply...